Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953772 | 0.78 | — | — | |
| SCHEMBL477611 | 0.76 | — | — | |
| SCHEMBL9625775 | 0.74 | HMGCR (0.47) | TSHRHPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4130265 | 0.74 | HMGCR (0.47) | TSHRHPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2395808 | 0.74 | HMGCR (0.47) | TSHRHPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10892322 | 0.74 | HMGCR (0.47) | TSHRHPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1399964 | 0.74 | HMGCR (0.47) | TSHRHPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29074826 | 0.73 | TSHR (0.46) | TSHRCYP3A4MAPTALDH1A1 | |
| SCHEMBL28230770 | 0.73 | TSHR (0.55) | TSHRCYP3A4HPGDSMN1; SMN2ATM | |
| SCHEMBL825898 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179804-B2 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050239776-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239776-A1 | Tachykinin receptor antagonists | TACR2, TACR1, PROKR1 | TSHR 337/4885CYP3A4 3767/4885HPGD 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.